Biotech | March 09, 2022
Alvotech settles with AbbVie to secure US rights to Humira biosimilar
Alvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023
Alvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023
Toyobo will start looking at ways to use the knowhow from DMC’s sophisticated fermentation process technologies to enhance the efficiency of making its bioproducts
Dr. Bibikova is an international leader with over 25 years of experience in genomics industry
Around 85% of ALS patients suffer from a progressive loss of bulbar functionality
Novel delivery of established growth and neurotrophic factors enables local, sustained release for greater efficacy
Brazil has the 4th largest pet market in the world with an estimated market size of BRL 1.8 billion, growing annually at 16%
This innovative biomanufacturing technology will help to deliver cost-effective viral production that is unmatched in the industry
Company has bought 7.73 million shares for KRW 146.1 billion thus securing the largest shareholder status in Bukwang Pharmaceutical
Collaboration with MTPC to discover novel hit compounds for multiple drug targets
It is a Phase 3 ready anti-myostatin adnectin for Spinal Muscular Atrophy (SMA).
Subscribe To Our Newsletter & Stay Updated
